Zacks Research Issues Pessimistic Forecast for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Investment analysts at Zacks Research reduced their Q4 2024 earnings per share estimates for shares of Pacira BioSciences in a note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.58 per share for the quarter, down from their prior estimate of $0.62. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.26 per share.

Several other research analysts also recently weighed in on the stock. JPMorgan Chase & Co. restated an “underweight” rating and set a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Truist Financial downgraded Pacira BioSciences from a “buy” rating to a “sell” rating and decreased their target price for the company from $30.00 to $8.00 in a research report on Tuesday, August 13th. Jefferies Financial Group boosted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. StockNews.com lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Finally, Royal Bank of Canada upped their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $23.50.

Pacira BioSciences Price Performance

Shares of PCRX opened at $17.81 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The business’s 50-day moving average is $16.53 and its two-hundred day moving average is $19.67. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $35.95. The company has a market capitalization of $822.29 million, a P/E ratio of -8.77 and a beta of 0.82.

Institutional Trading of Pacira BioSciences

Several institutional investors and hedge funds have recently bought and sold shares of PCRX. Jane Street Group LLC increased its position in shares of Pacira BioSciences by 1,780.2% during the first quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock valued at $5,480,000 after acquiring an additional 177,557 shares during the last quarter. Park Place Capital Corp acquired a new stake in Pacira BioSciences in the 2nd quarter valued at approximately $46,000. GAMMA Investing LLC raised its position in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after purchasing an additional 932 shares during the period. QRG Capital Management Inc. lifted its stake in Pacira BioSciences by 37.9% during the second quarter. QRG Capital Management Inc. now owns 31,309 shares of the company’s stock worth $896,000 after purchasing an additional 8,601 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Pacira BioSciences by 255.6% during the second quarter. SG Americas Securities LLC now owns 12,858 shares of the company’s stock worth $368,000 after buying an additional 9,242 shares during the period. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.